Research of assortment and price condition of the regional market of antidepressants for treatment of women in prenatal and postnatal periods

According to studies, depression in women occurs during pregnancy or within 4 weeks after delivery and can last up to 6 months. or even up to a year after birth. The most common in treating depression in pregnant women and during breastfeeding are antidepressants of selective serotonin reuptake inhibitors (SSRIs) group. The study aimed research the range and price situation in pharmacies (on the example of Lviv) of antidepressants SSRIs group used to treat depression in women in the prenatal and postnatal periods. The objects were the data of the State Register of Medicinal Products of Ukraine and the ATC / DDD Index 2021 and also information on the prices for medicines in pharmacies in Lviv and the average salary of full-time employees in Lviv region as of February 2021. Methods used: system, statistical, comparison analysis, generalization. It is shown that in Lviv pharmacies there were more than half of the trade names (TNs) of antidepressants of the SSRIs group registered in Ukraine. Based on 1 defined daily dose (DDD), on the one hand, competitive pricing and relative economic affordability for four-fifths of the studied drugs in terms of specific TNs, on the other ‒ a small number (14.6%) of the most affordable TNs antidepressants of the SSRIs group. We researched that there were six international non-proprietary names of antidepressants of the SSRIs group in the form of 77 trade names (TN) were registered in Ukraine in February 2021. There were only 41 or 53.9% of their TN was present in Lviv pharmacies. We determined that the lowest prices of 1 DDD among the TNs antidepressants of SSRIs group are characteristic of Fluxen capsules № 30 and Fluoxetine 20 mg tablets of Ukrainian production. The highest prices of 1 DDD are inherent in the Cipramil 20 mg tablets and Cipralex 10 mg tablets of Danish production. We found that the overall value of the price liquidity ratio for the vast majority (33 or 80,5% out of 41 TNs) antidepressants of SSRIs group of TNs present in pharmacies in Lviv does not exceed 0.5, which indicates an intensely competitive environment in the regional market of these drugs and the relative availability in pharmacies of a particular TN of the studied antidepressants. On the other hand, the most affordable for a price of 1 DDD were only 6 or 14.6% of TNs antidepressants of the SSRIs group, which have low values of affordability.